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Prevalence of menopausal symptoms
among mid-life women: findings from
electronic medical records
Matthew Sussman1, Jeffrey Trocio2, Craig Best3, Sebastian Mirkin2, Andrew G. Bushmakin2, Robert Yood3,
Mark Friedman1, Joseph Menzin1* and Michael Louie2
Abstract
Background: To assess the prevalence of menopausal symptoms among women prescribed hormone therapy (HT)
using electronic medical record data from a regional healthcare organization.
Methods: Retrospective data from the Reliant Medical Group from 1/1/2006-12/31/2011 were assessed for 102
randomly-selected patients. Study eligibility criteria included: females aged 45 to 65; prescribed oral or transdermal
HT; no history of breast cancer, venous thromboembolism, stroke, gynecological cancer, or hysterectomy;
continuously enrolled in the health plan for 1 year before and after the first observed HT prescription. Prevalence of
menopause-related symptoms was analyzed descriptively at both the patient and visit levels.
Results: Mean age of patients was 54 years. The most common menopausal symptoms were: hot flushes (40 %),
night sweats (17 %), insomnia (16 %), vaginal dryness (13 %), mood disorders (12 %), and weight gain (12 %).
Among the 102 patients, 163 individual visits listing menopausal symptoms were identified, of which hot flushes
(71 visits) were the most common symptom identified.
Conclusion: Our findings provide recent data on the types of menopausal symptoms experienced by mid-life
women prescribed HT. Electronic medical records may be a rich source of data for future studies of menopausal
symptoms in this population.
Background
Menopause, defined as the complete cessation of men-
strual periods, occurs naturally in most women and is as-
sociated with the gradual loss of ovarian follicles. With the
aging of the worldwide population in the coming decades,
it is estimated that 1.2 billion women worldwide will be
menopausal or postmenopausal by the year 2030 [1].
Common symptoms of menopause include vasomotor
symptoms (VMS, defined as hot flushes and/or night
sweats), sleep disturbances, and vaginal dryness [2]. It is
estimated that as many as 85 % of postmenopausal women
have experienced a menopause-related symptom in their
lifetime [3]. Prevalence of VMS alone is estimated at
approximately 40 to 50 million women in the United
States [4].
Symptom prevalence and severity generally increase
with advancing reproductive stage, which ranges from late
reproductive, early menopause transition, late menopause
transition, to postmenopause [3]. Currently, therapies tar-
geted to treat a variety of menopausal symptoms are
hormone-based. These therapies are generally more effect-
ive than non-hormonal treatments which generally treat a
single symptom. However, hormone therapy (HT) is not
indicated for women with past or existing breast cancer,
past or existing estrogen-sensitive malignant conditions,
undiagnosed genital bleeding, untreated endometrial
hyperplasia, venous thromboembolic event history, past
or existing arterial thromboembolic disease, untreated
hypertension, existing liver disease, hypersensitivity to the
active ingredients in HT, and porphyria cutanea tarda [5].
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Current guidelines recommend that HT is prescribed at
the lowest effective dose and for the shortest duration,
and be consistent with individual treatment goals among
postmenopausal women [6].
The primary objective of this study was to assess the
prevalence of menopausal symptom burden among
women prescribed HT using electronic medical record
(EMR) data. EMR systems are an emerging, rich data
source for capturing detailed information during real-
world medical encounters, and thus were the primary
vehicle for this analysis.
Methods
Overview
This study evaluated the prevalence and burden of
menopause-related symptoms among women aged 45 to
65 who had evidence of HT use. EMR data from a re-
gional healthcare organization were analyzed for preva-
lence of menopausal symptoms. Women were selected
for potential inclusion if they were enrolled in the Fallon
Community Health Plan for one year prior to and one
year following the first observed prescription for HT.
Data source
Data from the Reliant Medical Group, Worcester,
Massachusetts, USA were used to explore the prevalence
of menopausal symptoms among women undergoing HT.
The Reliant Medical Group is a multispecialty group prac-
tice with a predominantly managed-care population of ap-
proximately 200,000 patients. Data covering the six-year
period from January 1, 2006 through December 31, 2011
(the study period) were analyzed.
The study data set consisted of combined patient
medical claims and EMR data. Patients’ data were de-
identified, with a unique, encrypted identifier available
to link claims and EMR information. The study protocol
and data collection forms were approved by the Reliant
Medical Group-Fallon Community Health Plan-Saint
Vincent Hospital Institutional Review Board.
Patient selection
Patient IDs for EMR review were identified based on a
filled prescription for HT, using administrative claims data
from the Reliant Medical Group. Patients selected for
study inclusion were first identified using the following
claims-based eligibility criteria: female patients, fill of at
least one month’s supply of HT anytime between January
1, 2007 and December 31, 2010 (with the first date of HT
deemed the “index date” for analysis), and aged 45 to
65 years of age as of the index date. Patients were add-
itionally required to have no history of breast cancer, ven-
ous thromboembolism, stroke, gynecological cancer, or
total hysterectomy, and be continuously enrolled in the
health plan for 12 months pre- and 12 months post-index.
HT consisted of oral or transdermal estrogen or estrogen
and progestin combination therapies, excluding HT rings
and creams.
From the full list of patients meeting eligibility criteria
in claims data, a random sample of patients was generated
to serve as the cohort for the EMR review. Study inclusion
criteria, as first identified via claims data, were confirmed
through the EMR chart review by clinical professionals
from the Reliant Medical Group until approximately 100
patients met eligibility criteria, representing approximately
one-third of patients meeting claims eligibility criteria.
Menopausal symptom identification
All patient visits in the EMR (excluding behavioral man-
agement visits) occurring within the two-year study
period were analyzed. Data variables extracted from the
EMR data set included: visit date, reason for the visit,
provider specialty, and whether any menopausal symp-
toms were listed during the visit. All symptoms were re-
quired to have menopause referenced in the physician
notes of the EMR as the cause of the symptom. Symp-
toms could have been self-reported by the patient or
elicited by the healthcare provider. Specific menopause
symptoms evaluated included: hot flushes (used inter-
changeably with hot flashes), night sweats, insomnia, va-
ginal dryness, loss of sexual desire, weight gain, hair loss,
fatigue, major depression, anxiety, or mood disorders
(including mention of episodic mood disorder and/or
mood swings). VMS was defined based on the presence
of hot flushes and/or night sweats, which is consistent
with the National Institute of Health (NIH) definition of
VMS [7].
Data analysis
The prevalence of all identified symptoms was analyzed
descriptively at both the patient and visit levels. Descrip-
tive analyses of all patient characteristics were con-
ducted. Binary variables were summarized using
percentages of patients and continuous variables were
summarized using mean, SD, and median values. All
analyses were conducted with SAS v9.3, Cary, North
Carolina, USA.
Results
Patient characteristics
A total of 102 patients were randomly selected from the
administrative claims data and met inclusion criteria for
full EMR chart review. The highest proportion of pa-
tients was between 50-54 years of age (41 %), while 33 %
were aged 55-59. Overall, the mean (±SD) age was 54
(±5) years. Approximately one-third of patients were cat-
egorized as being normal weight (32 %), overweight
(34 %), or obese/morbidly obese (29 %) (Table 1).
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Menopausal symptom identification
At the patient level, the most common menopausal
symptoms identified during the study period using EMR
data were: hot flushes (40 %), followed by night sweats
(17 %), insomnia (16 %), vaginal dryness (13 %), mood
disorders (12 %), and weight gain (12 %) (Fig. 1). 45 % of
the patients presented with VMS (either hot flushes or
night sweats).
Among the 102 patients included in this analysis, a
total of 163 individual visits listed menopausal symp-
toms during the study period. Similar to the patient-
level analysis, the most common symptom identified in
visit-level EMR data were hot flushes (71 visits, 44 % of
individual visits), the estimates for which indicate that
some patients had more than one complaint.
Provider specialty
For visits with any menopausal symptom identified, the
highest proportion of patients were seen by an OB/GYN
(46 %), followed by 36 % for internal medicine, 10 % for
family practitioner, and 8 % for other specialty type.
More specifically, the vast majority of hot flushes and
night sweats were identified by either an OB/GYN or an
internal medicine physician.
Discussion
Summary
This analysis examined menopausal symptoms among
102 midlife women in a Massachusetts-based healthcare
organization. Results from this analysis provide recent
data on the types of menopausal symptoms experienced
among midlife women prescribed HT. Approximately
half of women were found to experience hot flushes.
Comparison to literature
Following a comprehensive search of the literature, we
were unable to find any published studies using EMR
data to assess menopausal symptom burden. Studies
using alternative methodologies to assess the prevalence
of various menopausal symptoms exist [8–11]; however,
it is difficult to directly compare their results to those
from our study.
For instance, two studies [8, 9] used survey-based
methodology to determine prevalence rates of meno-
pausal symptoms, yet this technique does not represent
real-world practice as patients may be more willing to
disclose sensitive symptoms given the private format of
administering and completing surveys. Another study
used face-to-face interviews to collect data on meno-
pausal symptoms [10]; however, not all patients in the
study were required to be on HT, therefore limiting the
comparability to our population of women prescribed
HT. Conducting survey-based research is expensive and
time consuming, due to efforts to design the survey, to
prepare documents for institutional review board ap-
proval, to administer the survey, and to collect and enter
data for analysis. EMR data, in contrast, offers the bene-
fit of providing ready access to up-to-date information
and is an emerging source for patient data given the pro-
liferation of EMR systems in recent years [12].
Menopausal symptom burden was also assessed in the
context of a prospective observational study, which in-
cluded follow-up visits to specifically evaluate rates of
menopausal symptoms. Follow-up focused on meno-
pausal symptoms likely led to higher prevalence esti-
mates than what would be expected to be captured in
real-world practice such as our study [11].
Finally, we were unable to identify any studies that
used administrative claims data to assess our research
objectives. There are a variety of reasons of why this
Table 1 Demographic characteristics of patient sample
Characteristic Estimate
Patients (N) 102
Age (%)
45 - 49 11.8 %
50 - 54 41.2 %
55 - 59 33.3 %
60 - 65 13.7 %
Mean 54
SD 5
Median 54
Height as of index date (inches)
Mean 63.9
SD 2.3
Median 64.0
Weight as of index date (pounds)
Mean 163.7
SD 36.6
Median 158.0
Missing (%) 1.0 %
Body mass index
Mean 28.1
SD 6.4
Median 26.9
Obesity status (%)a
Underweight 2.0 %
Normal 32.4 %
Overweight 34.3 %
Obese 24.5 %
Morbidly obese 4.9 %
Missing (%) 2.0 %
Index was defined as the date of the first HT use
aUnderweight: BMI <18.5; Normal: 18.5 ≤ BMI to < 25; Overweight: 25 ≤ BMI < 30;
Obese: 30 ≤ BMI < 40; Morbidly Obese: BMI ≥ 40
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may be the case. While accurate in identifying many
common diagnoses, administrative claims data are sub-
ject to medical coding errors since not all services are
billed [13]. Diagnoses recorded in claims may be limited
to a select few diagnoses associated with an office visit,
as opposed to the more complete set of information
available in physician notes in an EMR system. This dis-
crepancy in diagnoses may be of particular importance
among women treated for menopause with HT, where
an annual visit to the gynecologist or primary care pro-
vider may be simply listed in claims as a general medical
examination, rather than including the full set of symp-
toms discussed during the visit.
Limitations
The application of EMR data to this analysis carries cer-
tain limitations which may have contributed to an
underestimation of symptom prevalence. For instance,
the EMR analysis relied on patients to report relevant
information regarding menopausal symptoms to their
healthcare providers. For symptoms deemed to be highly
sensitive, patients may have chosen not to report such
symptoms to their providers. Similarly, the symptoms re-
corded in the EMR system were at the discretion of the
attending healthcare provider. It is possible that some
complaints deemed to be non-severe and/or not requir-
ing treatment were not recorded in the EMR. It is also
important to note that the severity of symptoms could
not be identified based on data extracted from the EMR.
For patients who were seen at providers outside of the
Reliant Medical Group, symptoms would not have been
captured in the EMR system. Additionally, symptoms not
directly documented by the physician as menopause-
related were not analyzed in the EMR data. Moreover, the
duration of HT use was not captured in the data set,
which may have had an impact on the prevalence and/or
severity of menopausal symptoms. Finally, the data set an-
alyzed in the present study was limited to patients
enrolled in the Fallon Community Health Plan which
covers only the Massachusetts area, and therefore does
not provide nationally-representative estimates.
Conclusion
This study confirmed that EMR data may be a rich
source of information regarding menopausal symptoms
among women prescribed HT. Our study provides
current estimates of the symptom burden among women
undergoing HT, with approximately half of patients
reporting VMS in clinical practice. As the use of EMR
systems grow, these data may become increasingly useful
as a source of patient-reported outcomes information.
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